157 related articles for article (PubMed ID: 38305293)
1. Current evidence on local therapy in oligometastatic prostate cancer.
Basourakos SP; Henning G; Karnes RJ
Curr Opin Urol; 2024 May; 34(3):198-203. PubMed ID: 38305293
[TBL] [Abstract][Full Text] [Related]
2. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer.
Jalfon MJ; Sakhalkar OV; Lokeshwar SD; Marks VA; Choksi AU; Klaassen Z; Leapman MS; Kim IY
Curr Urol Rep; 2023 Oct; 24(10):455-461. PubMed ID: 37369828
[TBL] [Abstract][Full Text] [Related]
3. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
4. Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives.
Tsaur I; Blaheta RA; Dotzauer R; Brandt MP; Gandaglia G; Sinescu I; Mirvald C; Olivier J; Surcel C;
World J Urol; 2023 Aug; 41(8):2077-2090. PubMed ID: 36183289
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.
Zhao X; Xiao YT; Yang Y; Ye Y; Chang Y; Jiang L; Eftekhar M; Ren S; Zhang H
Cancer Control; 2022; 29():10732748221120462. PubMed ID: 35980734
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
[TBL] [Abstract][Full Text] [Related]
7. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
9. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial.
Dai B; Zhang S; Wan FN; Wang HK; Zhang JY; Wang QF; Kong YY; Ma XJ; Mo M; Zhu Y; Qin XJ; Lin GW; Ye DW
Eur Urol Oncol; 2022 Oct; 5(5):519-525. PubMed ID: 35780048
[TBL] [Abstract][Full Text] [Related]
10. Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?
Cahill EM; Pfail JL; Fu MZ; Saraiya B; Mayer T; Stephenson RD; Ennis RD; Hathout L; Deek MP; Ghodoussipour S; Jang TL
Curr Urol Rep; 2023 Jul; 24(7):299-306. PubMed ID: 37017928
[TBL] [Abstract][Full Text] [Related]
11. A narrative review of oligometastatic prostate cancer-an evolving paradigm.
Sritharan K; Rieu R; Tree A
Ann Palliat Med; 2021 May; 10(5):5969-5987. PubMed ID: 33752437
[TBL] [Abstract][Full Text] [Related]
12. What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
Baboudjian M; Roubaud G; Fromont G; Gauthé M; Beauval JB; Barret E; Brureau L; Créhange G; Dariane C; Fiard G; Mathieu R; Ruffion A; Rouprêt M; Renard-Penna R; Sargos P; Ploussard G;
World J Urol; 2023 Aug; 41(8):2033-2041. PubMed ID: 36484817
[TBL] [Abstract][Full Text] [Related]
13. The cytoreductive radical prostatectomy in metastatic prostate cancer.
Vladimír Š; Zuzana S; Hana Š
Klin Onkol; 2022; 35(1):55-62. PubMed ID: 35236082
[TBL] [Abstract][Full Text] [Related]
14. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience.
Boeri L; Sharma V; Kwon E; Stish BJ; Davis BJ; Karnes RJ
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):514-523. PubMed ID: 33268854
[TBL] [Abstract][Full Text] [Related]
15. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P; Reynders D; Decaestecker K; Fonteyne V; Lumen N; De Bruycker A; Lambert B; Delrue L; Bultijnck R; Claeys T; Goetghebeur E; Villeirs G; De Man K; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; De Meerleer G
J Clin Oncol; 2018 Feb; 36(5):446-453. PubMed ID: 29240541
[TBL] [Abstract][Full Text] [Related]
16. Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy.
Wenzel M; Garcia CC; Hoeh B; Jorias C; Humke C; Koll F; Tselis N; Rödel C; Graefen M; Tilki D; Chun FKH; Mandel P
Prostate; 2023 Oct; 83(14):1365-1372. PubMed ID: 37464963
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.
Zhao X; Wang T; Ye Y; Li J; Gao X; Zhang H
BMJ Open; 2022 Sep; 12(9):e051371. PubMed ID: 36180115
[TBL] [Abstract][Full Text] [Related]
18. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract][Full Text] [Related]
19. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer.
Ranasinghe W; Chapin BF; Kim IY; Sooriakumaran P; Lawrentschuk N
BJU Int; 2020 Jun; 125(6):792-800. PubMed ID: 32176456
[TBL] [Abstract][Full Text] [Related]
20. Emerging role for local therapy in oligometastatic prostate cancer.
Khondakar NR; Owens-Walton J; Daneshvar M; Williams C; O'Connor L; Yerram NK; Pinto PA
Clin Adv Hematol Oncol; 2021 Jul; 19(7):460-467. PubMed ID: 34236345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
